TRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report released on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a neutral rating on shares of TRACON Pharmaceuticals in a report on Monday, July 1st.

TRACON Pharmaceuticals Price Performance

NASDAQ:TCON opened at $0.11 on Friday. The stock’s fifty day moving average price is $0.12 and its two-hundred day moving average price is $1.45. The company has a market cap of $392,064.75, a P/E ratio of 0.17 and a beta of 1.36. TRACON Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $14.75.

TRACON Pharmaceuticals (NASDAQ:TCON) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) EPS for the quarter. The business had revenue of $0.06 million for the quarter.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.